We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Dietary Supplements: Safety Issues and Quality Control—Reply

Brian F. McBride, PharmD
Arch Intern Med. 2011;171(5):476-477. doi:10.1001/archinternmed.2011.54.
Text Size: A A A
Published online


In reply

We thank Glisson and colleagues for their letter and their recognition of the inherent limitations of the research of dietary supplements marketed to consumers. The purpose of my laboratory is to conduct phase 1 electrocardiographic studies of commercially marketed herbal supplements to healthy volunteers. In this way, we strive to closely simulate the actual scenario in which a patient would purchase a product “off the shelf” at his or her local drug store and potentially experience a clinical adverse drug event during the course of self-administration. To that end, Glisson and colleagues attempt to establish the hypothesis that our study is flawed because research has shown that selected dietary supplements have demonstrated interlot and intralot variability. However, Glisson and colleagues have not produced evidence showing that the specific product we tested (Enzyte) has demonstrated interlot or intralot variability. Moreover, the Food and Drug Administration, on June 22, 2007, published a final rule requiring manufacturers of dietary supplements to adhere to current good manufacturing practices. Among other things, the final rule states that manufacturers of dietary supplements must maintain proper manufacturing operations and quality control procedures and perform end process and/or in-process testing of all components included in the preparation.1 To date, there has been no evidence that Vianda, LLC, has failed to comply with this rule.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





March 14, 2011
Brian F. McBride, PharmD
Arch Intern Med. 2011;171(5):476-477. doi:10.1001/archinternmed.2011.54.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Future perspectives in Orbitrap™ high resolution mass spectrometry in food analysis - a review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess Published online Jun 8, 2015;